Amgen is spending more than $26 billion to dive deeper into rare disease treatments with a deal for Deerfield-based drugmaker Horizon Therapeutics.
Amgen is spending more than $26 billion to dive deeper into rare disease treatments with a deal for Deerfield-based drugmaker Horizon Therapeutics.